Drug Interactions between Entresto and tepotinib
This report displays the potential drug interactions for the following 2 drugs:
- Entresto (sacubitril/valsartan)
- tepotinib
Interactions between your drugs
No interactions were found between Entresto and tepotinib. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Entresto
A total of 334 drugs are known to interact with Entresto.
- Entresto is in the drug class angiotensin receptor blockers and neprilysin inhibitors.
- Entresto is used to treat Heart Failure.
tepotinib
A total of 288 drugs are known to interact with tepotinib.
- Tepotinib is in the drug class multikinase inhibitors.
- Tepotinib is used to treat Non Small Cell Lung Cancer.
Drug and food interactions
valsartan food
Applies to: Entresto (sacubitril / valsartan)
GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.
MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.
References (2)
- (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
- (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals
tepotinib food
Applies to: tepotinib
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of tepotinib. When tepotinib was administered after a high-fat, high-calorie meal (approximately 800 to 1000 calories; 150 calories from protein, 250 calories from carbohydrate, 500 to 600 calories from fat), tepotinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2-fold and 1.6-fold, respectively, compared to administration under fasted conditions.
MANAGEMENT: Tepotinib should be administered with food at approximately the same time each day.
References (1)
- (2021) "Product Information. Tepmetko (tepotinib)." EMD Serono Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.